Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,452,178
  • Shares Outstanding, K 57,889
  • Annual Sales, $ 103,710 K
  • Annual Income, $ -402,730 K
  • 60-Month Beta 2.15
  • Price/Sales 24.84
  • Price/Cash Flow N/A
  • Price/Book 3.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.61
  • Number of Estimates 9
  • High Estimate -1.36
  • Low Estimate -1.95
  • Prior Year -1.82
  • Growth Rate Est. (year over year) +11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.99 +38.54%
on 03/17/20
57.75 -23.26%
on 03/03/20
-11.76 (-20.97%)
since 02/28/20
3-Month
31.99 +38.54%
on 03/17/20
64.24 -31.01%
on 02/14/20
+0.91 (+2.10%)
since 12/27/19
52-Week
31.99 +38.54%
on 03/17/20
74.50 -40.51%
on 04/05/19
-25.04 (-36.10%)
since 03/29/19

Most Recent Stories

More News
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare...

RARE : 44.32 (+4.63%)
Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 44.32 (+4.63%)
Ultragenyx to Present at Barclays Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp,...

RARE : 44.32 (+4.63%)
Ultragenyx Announces Planned Transition of Chief Financial Officer

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that Shalini Sharp will...

RARE : 44.32 (+4.63%)
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita(R) (burosumab) for Tumor-Induced Osteomalacia (TIO)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin Co., Ltd....

RARE : 44.32 (+4.63%)
Ultragenyx to Present at SVB Leerink Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg,...

RARE : 44.32 (+4.63%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

BAYRY : 14.5800 (+3.74%)
RARE : 44.32 (+4.63%)
AVXL : 3.01 (+3.08%)
GH : 71.25 (+5.10%)
Ultragenyx: 4Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $93.8 million in its fourth quarter.

RARE : 44.32 (+4.63%)
Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

2019 total revenue is $103.7 million; 2019 Crysvita (burosumab) revenue to Ultragenyx is $87.3 million

RARE : 44.32 (+4.63%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host...

RARE : 44.32 (+4.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 46.75
1st Resistance Point 45.54
Last Price 44.32
1st Support Level 42.31
2nd Support Level 40.29

See More

52-Week High 74.50
Fibonacci 61.8% 58.26
Fibonacci 50% 53.24
Fibonacci 38.2% 48.23
Last Price 44.32
52-Week Low 31.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar